Adolescent cannabinoid exposure reduced cocaine reward in adult mice and changed epigenetic markers

Adolescent WIN55,212-2 exposure did not alter anxiety or depression in adulthood. However, it blocked cocaine-induced conditioned place preference (a measure of drug reward) without affecting cocaine-induced hyperlocomotion. This was accompanied by increased expression of DNA methyltransferase 3a (DNMT3a) in the prefrontal cortex, suggesting epigenetic changes may modulate cocaine reward sensitivity.

Swiss mice received WIN55,212-2 during adolescence. In adulthood, tested for anxiety (elevated plus maze), depression (forced swim), locomotor activity, and cocaine reward (conditioned place preference). DNMT3a expression measured by real-time PCR in prefrontal cortex.

Counter to the gateway hypothesis, this study found adolescent cannabinoid exposure actually reduced cocaine reward sensitivity. The epigenetic mechanism (DNMT3a upregulation) provides a molecular explanation for how early cannabinoid exposure could alter drug reward processing.

The finding that adolescent cannabinoid exposure increased DNMT3a (a DNA methylation enzyme) and reduced cocaine reward adds complexity to the gateway drug debate. Rather than sensitizing the brain to other drugs, cannabinoid exposure may actually dampen reward responses through epigenetic reprogramming.

Synthetic cannabinoid (WIN55,212-2) may not represent natural cannabis use. Male mice only. Conditioned place preference is one measure of reward; other aspects of addiction (compulsive seeking, relapse) not tested. DNMT3a change is correlational, not proven causal.